The report of Deloitte's rapid review reads more like a case to reverse the defunding decision and for the removal of the officials responsible for the administration of federally-funded quality use programs.
Did anyone actually read this report before confirming the decision?
September 16, 2022 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Frustrated minister encourages an early negotiation of new agreements
May 14, 2026 - - Latest News -
Long-term study finds continuing Mounjaro helps maintain weight loss
May 14, 2026 - - Latest News -
GBMA welcomes Budget pathway to increasing biosimilar uptake
May 14, 2026 - - Latest News -
There are a number of reasons to criticise the minister on the PBS, but he is right to be annoyed about this
May 14, 2026 - - Latest News -
Disappointment for diabetes advocates in response to Government budget silence
May 13, 2026 - - Latest News -
Updated forecast highlights the real risk of relying on these numbers
May 13, 2026 - - Latest News -
Baxter and MTAA launch Australian Healthcare Manufacturing Leaders Network
May 13, 2026 - - Latest News
